WO2000042907A1 - System and method for noninvasive blood analyte measurements - Google Patents
System and method for noninvasive blood analyte measurements Download PDFInfo
- Publication number
- WO2000042907A1 WO2000042907A1 PCT/US2000/001378 US0001378W WO0042907A1 WO 2000042907 A1 WO2000042907 A1 WO 2000042907A1 US 0001378 W US0001378 W US 0001378W WO 0042907 A1 WO0042907 A1 WO 0042907A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calibration
- class
- classes
- membership
- classification
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 102
- 239000008280 blood Substances 0.000 title claims abstract description 102
- 239000012491 analyte Substances 0.000 title claims abstract description 72
- 238000005259 measurement Methods 0.000 title claims description 88
- 238000000034 method Methods 0.000 title claims description 81
- 230000003595 spectral effect Effects 0.000 claims abstract description 52
- 238000000862 absorption spectrum Methods 0.000 claims abstract description 49
- 230000035790 physiological processes and functions Effects 0.000 claims abstract description 12
- 238000001727 in vivo Methods 0.000 claims abstract description 4
- 210000001519 tissue Anatomy 0.000 claims description 57
- 239000013598 vector Substances 0.000 claims description 45
- 230000006870 function Effects 0.000 claims description 41
- 238000001228 spectrum Methods 0.000 claims description 30
- 238000002835 absorbance Methods 0.000 claims description 27
- 238000000605 extraction Methods 0.000 claims description 22
- 238000007781 pre-processing Methods 0.000 claims description 21
- 238000004422 calculation algorithm Methods 0.000 claims description 18
- 238000013507 mapping Methods 0.000 claims description 17
- 230000009466 transformation Effects 0.000 claims description 13
- 210000000577 adipose tissue Anatomy 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 230000003287 optical effect Effects 0.000 claims description 10
- 238000013528 artificial neural network Methods 0.000 claims description 9
- 238000003909 pattern recognition Methods 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 230000036571 hydration Effects 0.000 claims description 7
- 238000006703 hydration reaction Methods 0.000 claims description 7
- 230000002452 interceptive effect Effects 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 238000011481 absorbance measurement Methods 0.000 claims description 5
- 238000004364 calculation method Methods 0.000 claims description 5
- 238000013145 classification model Methods 0.000 claims description 5
- 238000012937 correction Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 230000007613 environmental effect Effects 0.000 claims description 4
- 238000009499 grossing Methods 0.000 claims description 4
- 238000005534 hematocrit Methods 0.000 claims description 4
- 238000000844 transformation Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 238000000354 decomposition reaction Methods 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 230000006978 adaptation Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 238000000691 measurement method Methods 0.000 claims description 2
- 238000010606 normalization Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 238000011524 similarity measure Methods 0.000 claims description 2
- 238000012567 pattern recognition method Methods 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 239000008103 glucose Substances 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 18
- 238000013459 approach Methods 0.000 description 17
- 238000010586 diagram Methods 0.000 description 17
- 238000010238 partial least squares regression Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 5
- 238000004497 NIR spectroscopy Methods 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000013450 outlier detection Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000007621 cluster analysis Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000001320 near-infrared absorption spectroscopy Methods 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 238000012628 principal component regression Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000596041 Homo sapiens Plastin-1 Proteins 0.000 description 1
- 101000596046 Homo sapiens Plastin-2 Proteins 0.000 description 1
- 101000596119 Homo sapiens Plastin-3 Proteins 0.000 description 1
- 240000002329 Inga feuillei Species 0.000 description 1
- 101000800755 Naja oxiana Alpha-elapitoxin-Nno2a Proteins 0.000 description 1
- 102100035181 Plastin-1 Human genes 0.000 description 1
- 102100035182 Plastin-2 Human genes 0.000 description 1
- 102100035220 Plastin-3 Human genes 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013144 data compression Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003045 statistical classification method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/4785—Standardising light scatter apparatus; Standards therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0223—Operational features of calibration, e.g. protocols for calibrating sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/107—Measuring physical dimensions, e.g. size of the entire body or parts thereof
- A61B5/1075—Measuring physical dimensions, e.g. size of the entire body or parts thereof for measuring dimensions by non-invasive methods, e.g. for determining thickness of tissue layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Definitions
- the invention relates to the measurement of blood analytes. More particularly, the invention relates to an intelligent system for noninvasive blood analyte prediction.
- NIR near infrared
- the absorbance of light at each wavelength is a function of the structural properties and chemical composition of the tissue.
- Tissue layers each containing a unique heterogeneous particulate distribution, affect light absorbance through scattering.
- Chemical components such as water, protein, fat and blood analytes, absorb light proportionally to their concentration through unique absorption profiles or signatures.
- the measurement of blood analyte concentrations is based on detecting the magnitude of light attenuation caused by the absorption signature of the targeted analyte.
- the process of calibration is the development of a mathematical transformation or model which estimates the blood analyte concentration from the measured tissue absorbance spectrum.
- accurate noninvasive estimation of blood analytes is presently limited by the dynamic nature of the sample, the skin and living tissue of the subject. Chemical, structural and physiological variations occur that produce dramatic changes in the optical properties of the tissue sample.
- Bodwell A new approach for the estimation of body composition: infrared interactance, The American Journal of Clinical Nutrition, 40, pp. 1123-1140 (Dec. 1984); S. Homma, T. Fukunaga, A. Kagaya, Influence of adipose tissue thickness in near infrared spectroscopic signals in the measurement of human muscle, Journal of Biomedical Optics, 1 (4), pp. 418-424 (Oct. 1996); A. Profio, Light transport in tissue, Applied Optics, vol. 28(12), pp. 2216-2222 (June 1989); and M. Van Gemert, S. Jacques, H. Sterenborg, W. Star, Skin optics, IEEE Transactions on Biomedical Engineering, vol. 36(12), pp. 1146-1154 (Dec. 1989).
- tissue measurement site has multiple layers and compartments of varied composition and scattering.
- the spectral absorbance versus wavelength is related to a complex combination of the optical properties and composition of these tissue components. Therefore, a general representation or model of the tissue absorbance spectrum is nonlinear and difficult to realize on the basis of first principles.
- Variations in the subject's physiological state effect the optical properties of tissue layers and compartments over a relatively short period of time. Such variations, for example, may be related to hydration levels, changes in the volume fraction of blood in the tissue, hormonal stimulation, temperature fluctuations and blood hemoglobin levels.
- tissue characteristics of individuals differ as a result of factors that include hereditary, environmental influences, the aging process, sex and body composition. These differences are largely anatomical and can be categorized as slowly varying structural properties producing diverse tissue geometry. Consequently, the tissue of a given subject has distinct systematic spectral absorbance features or patterns that can be related directly to specific characteristics such as dermal thickness, protein levels and percent body fat.
- the invention provides a method and apparatus for compensating for covariation of spectrally interfering species, sample heterogeneity, state variations, and structural variations through an intelligent pattern recognition system that is capable of determining calibration models that are most appropriate for the subject at the time of measurement.
- the calibration models are developed from the spectral absorbance of a representative population of subjects that have been segregated into groups.
- the groups or classes are defined on the basis of structural and state similarity, such that the variation within a class is small compared to the variation between classes. Classification occurs through extracted features of the tissue absorbance spectrum related to the current subject state and structure.
- the invention provides an intelligent system for measuring blood analytes noninvasively.
- the system operates on a near infrared absorbance spectrum of in vivo skin tissue.
- the hierarchical architecture employs a pattern classification engine to adapt the calibration to the structural properties and physiological state of the subject as manifested in the absorbance spectrum.
- a priori information about the primary sources of sample variability is used to establish general categories of subjects.
- the spectral interference is reduced by applying calibration schemes specific to the various categories, resulting in improved prediction accuracy and parsimonious calibrations.
- Two classification rules are disclosed:
- the second rule uses fuzzy set theory to develop calibration models and blood analyte predictions. Therefore, each calibration sample has the opportunity to influence more than one calibration model according to its class membership. Similarly, the predictions from more than one calibration are combined through defuzzification to produce the final blood analyte prediction.
- Fig. 1 is a block schematic diagram of an architecture of an intelligent system for noninvasive measurement of blood analytes according to the invention
- Fig. 2 is a typical noninvasive absorbance spectrum
- Fig. 3 is a block schematic diagram of a pattern classification system according to the invention.
- Figs. 4A and 4B provide two different flow diagrams showing two embodiments of the herein disclosed pattern classification system, where Fig. 4A shows subject classes that are mutually exclusive, and where Fig. 4B shows fuzzy classification applied to assign class membership to more than one class, both according to the invention;
- Fig. 5 is a block schematic diagram showing a general calibration system for mutually exclusive classes according to the invention.
- Fig. 6 is a block schematic diagram showing an example of parallel calibration models for mutually exclusive classes according to the invention
- Fig. 7 is a block schematic diagram showing a general calibration system for fuzzy class assignments according to the invention
- Fig. 8 is a block schematic diagram showing an example of parallel calibration models for fuzzy set assignments according to the invention.
- Fig. 9 is a block schematic diagram of an intelligent measurement system instrument according to the invention.
- Fig. 10 is a block schematic diagram of the intelligent measurement system with crisp classification rules according to the invention.
- Fig. 11 is a flow diagram showing processing steps for preprocessing 1 and feature extraction 1 of Fig. 10, according to the invention.
- Fig. 12 is a flow diagram showing processing steps of preprocessing 2 and feature extraction 2 of Fig. 10, according to the invention.
- Fig. 13 is a block schematic diagram showing membership rules according to the invention.
- Fig. 14 is a block schematic diagram of an intelligent measurement system with fuzzy classification according to the invention.
- Fig. 15 is a flow diagram showing preprocessing a feature extraction processes for the fuzzy classification system shown in Fig. 14, according to the invention.
- Fig. 16 provides a pair of graphs that plot the membership function for the fuzzy classification system of Fig. 14, where two features are used to determine the degree of membership in the sex and age related sub-sets, according to the invention
- Fig. 17 is a block schematic diagram showing fuzzy membership rules according to the invention.
- Fig. 18 is a block schematic diagram showing the defuzzification process according to the invention.
- the intelligent measurement system herein disclosed provides improved NIR noninvasive blood analyte measurement accuracy. This is accomplished by defining subpopulations or classes of subjects whose structure and state produce similarly featured NIR absorbance spectra. The classes have improved homogeneity leading to a reduction in variation related to the optical properties and composition of the sample. Because the interference is reduced while the magnitude of the blood analyte absorbance signal is unchanged, a substantial increase in signal-to-noise ratio is realized.
- IMS intelligent measurement system
- the architecture of the IMS is shown in Fig. 1 and consists of a conventional three- layer hierarchy (see, for example, P. Antsaklis, K.Passino, ed., An Introduction to Intelligent and Autonomous Control. Boston: Kluwer Academic Publishers (1992)) that operates in conjunction with an algorithm manager 10.
- the execution layer 16 receives the tissue absorbance spectrum from an instrument 28 and performs rudimentary preprocessing 29.
- the coordination layer 14 performs feature extraction 25.
- a classification system 26 is used to classify the subject according to extracted features that represent the state and structure of a sample. Based on the classification, the predictions from one or more existing calibration models 27 are used to form a glucose estimate 24.
- the classification and blood analyte prediction are passed to the management level 12 and action is taken based on the certainty of the estimate.
- the management level is also responsible for coordinating 22 all algorithmic events, monitoring the performance 21 based on the class, adapting the rules 20 as necessary, and maintaining information regarding system state 23.
- the first approach uses classes that are mutually exclusive.
- the second approach applies fuzzy set theory to form a classifier and prediction rules which allow membership in more than one class.
- the framework also allows for the detection of outliers, the determination of samples that are significantly different from the existing classes, and long-term monitoring of the system performance.
- the sample measurement or tissue absorbance spectrum is the vector me i N of absorbance values pertaining to a set of N wavelengths ⁇ e i N that span the near infrared (700 to 2500nm).
- a typical plot of versus ⁇ is shown in Fig. 2.
- the number of necessary wavelengths is a function of the cross correlation between the target analyte and the interfering species. For noninvasive applications with significant variation within and between individuals, the entire spectrum is useful.
- Preprocessing 29 includes operations such as scaling, normalization, smoothing, derivatives, filtering and other transformations that attenuate the noise and instrumental variation without affecting the signal of interest.
- the preprocessed measurement, e R w is determined according to:
- a set of subject groups or classes exists with members that are defined by the similarity of specific features. Grouping of the subjects according to the features reduces the spectral variation related the diverse structural properties of the subject population and physiological states encountered.
- the spectral absorbance measurements corresponding to the classes are more homogeneous than the entire population.
- the magnitude of the spectral signal of the target analyte remains unchanged. Therefore, calibration models for predicting blood analytes that are specific to subject classes are expected to be less complex and have an improved level of accuracy.
- the pattern recognition system is designed to classify new spectral measurements into the previously defined classes through structural and state similarities as observed in the tissue absorbance spectrum. Class membership is an indication of which calibration model(s) is(are) most likely to estimate the concentration of the target blood analyte accurately. Therefore, the pattern classification system is the essence of the proposed intelligent measurement system shown in Fig. 1.
- Fig. 3 is a more detailed representation of the pattern classification system.
- the system has two general functions:
- Feature extraction 25 is any mathematical transformation that enhances a particular aspect or quality of the data that is useful for interpretation.
- the classification model 30 is a method for determining a set of similarity measures with the predefined classes.
- the decision rule is the assignment of class membership 32 on the basis of a set of measures calculated by a decision engine 31 (see, for example, R. Duda, P. Hart, Pattern Classification and Scene Analysis. John Wiley and Sons, New York (1973); and J. Schurmann, Pattern Classification. A Unified View of Statistical and Neural Approaches. John Wiley & Sons, Inc., New York (1996)).
- the first scheme shown in Fig. 4A, provides a classification system 43 that assumes that the classes are mutually exclusive and forces each measurement to be assigned to a single class 45.
- the scheme shown in Fig. 4B employs a fuzzy classifier 44 that is not mutually exclusive. This allows a sample to have membership in more than one class simultaneously and provides a number between zero and one indicating the degree of membership in each class 46.
- Feature extraction is any mathematical transformation that enhances a quality or aspect of the sample measurement for interpretation (see, for example, R. Duda, P. Hart, Pattern Classification and Scene Analysis. John Wiley and Sons, New York (1973)).
- the purpose of feature extraction in Fig. 1 is to represent concisely the structural properties and physiological state of the tissue measurement site.
- the set of features is used to classify the subject and determine the calibration model(s) most useful for blood analyte prediction.
- f. 9 ⁇ W ⁇ 9 ⁇ M is a mapping from the measurement space to the feature space.
- Decomposing f(») yields specific transformations, /; ⁇ •): i N ⁇ ( 3i M i for determining a specific feature.
- the dimension, M consult indicates whether the ith feature is a scalar or a vector and the aggregation of all features is the vector z.
- a feature When a feature is represented as a vector or a pattern, it exhibits a certain structure indicative of an underlying physical phenomenon.
- Abstract features do not necessarily have a specific interpretation related to the physical system. Specifically, the scores of a principal component analysis are useful features, although their physical interpretation is not always known.
- the utility of the principal component analysis is related to the nature of the tissue absorbance spectrum. The most significant variation in the tissue spectral absorbance is not caused by a blood analyte but is related to the state, structure, and composition of the measurement site. This variation is modeled by the primary principal components. Therefore, the leading principal components tend to represent variation related to the structural properties and physiological state of the tissue measurement site.
- Simple features are derived from an a priori understanding of the sample and can be related directly to a physical phenomenon.
- Useful features that can be calculated from NIR spectral absorbance measurements include but are not limited to:
- Thickness of adipose tissue see, for example, J. Conway, K. Norris, C. Bodwell, A new approach for the estimation of body composition: infrared interactance, The American Journal of Clinical Nutrition, 40, pp. 1123-1140 (Dec. 1984); and S.
- Spectral decomposition is employed to determine the features related to a known spectral absorbance pattern.
- Protein and fat for example, have known absorbance signatures that can be used to determine their contribution to the tissue spectral absorbance.
- the measured contribution is used as a feature and represents the underlying variable through a single value.
- demographic information such as age
- tissue spectral absorbance is not deterministic.
- dermal thickness and many other tissue properties are statistically related to age but also vary substantially as a result of hereditary and environmental influences. Therefore, factor based methods are employed to build models capable of representing variation in the measured absorbance related to the demographic variable.
- the projection of a measured absorbance spectrum onto the model constitutes a feature that represents the spectral variation related to the demographic variable.
- the compilation of the abstract and simple features constitutes the /W-dimensional feature space. Due to redundancy of information across the set of features, optimum feature selection and/or data compression is applied to enhance the robustness of the classifier.
- Feature extraction determines the salient characteristics of measurements that are relevant for classification.
- the goal of the classification step is to determine the calibration model(s) that is/are most appropriate for the measurement.
- the subject is assigned to one of many predefined classes for which a calibration model has been developed and tested. Because the applied calibration model is developed for similar tissue absorbance spectra, the blood analyte predictions are more accurate than those obtained from a universal calibration model.
- pattern classification generally involves two steps:
- the mapping measures the similarity of the features to predefined classes and the decision engine assigns class membership.
- the first method uses mutually exclusive classes and therefore assigns each measurement to one class.
- the second method uses a fuzzy classification system that allows class membership in more than one class simultaneously. Both methods require prior class definitions as described subsequently.
- Class definition is the assignment of the measurements in the exploratory data set to classes. After class definition, the measurements and class assignments are used to determine the mapping from the features to class assignments.
- Class definition is performed through either a supervised or an unsupervised approach (see, for example, J. Schurmann, Pattern Classification. A Unified View of Statistical and Neural Approaches. John Wiley & Sons, Inc., New York (1996)).
- supervised classes are defined through known differences in the data.
- the use of a priori information in this manner is the first step in supervised pattern recognition which develops classification models when the class assignment is known.
- the majority of observed spectral variation can be modeled by three abstract factors which are related to several physical properties including body fat, tissue hydration, and skin thickness. Categorizing subjects on the basis of these three features produces eight different classes if each feature is assigned a "high” and "low” value.
- the drawback of this approach is that attention is not given to spectral similarity and the number of classes tends to increase exponentially with the number of features.
- Unsupervised methods rely solely on the spectral measurements to explore and develop clusters or natural groupings of the data in feature space. Such an analysis optimizes the within cluster homogeneity and the between cluster separation. Clusters formed from features with physical meaning can be interpreted based on the known underlying phenomenon causing variation in the feature space. However, cluster analysis does not use a priori information and can yield inconsistent results.
- a combination of the two approaches is applied to use a priori knowledge and exploration of the feature space for naturally occurring spectral classes.
- classes are first defined from the features in a supervised manner. Each set of features is divided into two or more regions and classes are defined by combinations of the feature divisions.
- a cluster analysis is performed on the data and the results of the two approaches are compared. Systematically, the clusters are used to determine groups of classes that can be combined. After conglomeration the number of final class definitions is significantly reduced according to natural divisions in the data.
- classifier is designed through supervised pattern recognition.
- a model is created based on class definitions which transforms a measured set of features to an estimated classification. Because the ultimate goal of the classifier is to produce robust and accurate calibration models, an iterative approach must be followed in which class definitions are optimized to satisfy the specifications of the measurement system.
- the statistical classification methods are applied to mutually exclusive classes whose variation can be described statistically (see, for example, J. Schurmann, Pattern Classification. A Unified View of Statistical and Neural Approaches. John Wiley & Sons, Inc., New York (1996); and J. Bezdek, S. Pal, eds., Fuzzv Models for Pattern Recognition. IEEE Press, Piscataway, NJ (1992)).
- classifier is designed by determining an optimal mapping or transformation from the feature space to a class estimate which minimizes the number of misclassifications. The form of the mapping varies by method as does the definition of optimal.
- Existing methods include linear discriminant analysis (see, for example, R. Duda, P.
- the class is used to select or adapt the calibration model as discussed below in connection with calibration.
- a more appropriate method of class assignment is based on fuzzy set theory (see, for example, J. Bezdek, S. Pal, eds., Fuzzy Models for Pattern Recognition. IEEE Press, Piscataway, NJ (1992); C. Chen, ed., Fuzzy Logic and Neural Network Handbook. Piscatawav. NJ. IEEE Press (1996); and L. Zadeh, Fuzzy Sets, Inform. Control, vol. 8, pp. 338-353 (1965)).
- membership in fuzzy sets is defined by a continuum of grades and a set of membership functions that map the feature space into the interval [0,1] for each class.
- the assigned membership grade represents the degree of class membership with "1 " corresponding to the highest degree. Therefore, a sample can simultaneously be a member of more than one class.
- the membership vector provides the degree of membership in each of the predefined classes and is passed to the calibration algorithm.
- fuzzy class definitions similar to the methods previously described. Fuzzy cluster analysis can be applied and several methods, differing according to structure and optimization approach can be used to develop the fuzzy classifier. All methods attempt to minimize the estimation error of the class membership over a population of samples.
- Blood analyte prediction occurs by the application of a calibration model to the preprocessed measurement as depicted in Fig. 1.
- the proposed prediction system involves a calibration or set of calibration models that are adaptable or selected on the basis of the classification step.
- the following discussion describes the calibration system for the two types of classifiers.
- the designated classification is passed to a nonlinear model which provides a blood analyte prediction based on the subject classification and spectral measurement.
- This process illustrated in Fig. 5, involves the modification of the estimation strategy for the current subject according to the structural tissue properties and physiological state manifested in the absorbance spectrum.
- This general architecture necessitates a nonlinear calibration model 50, such as nonlinear partial least squares or artificial neural networks because the mapping is highly nonlinear.
- a different calibration 60 is realized for each class.
- the estimated class is used to select one of p calibration models most appropriate for blood analyte prediction using the current measurement.
- k is the class estimate for the measurement, the blood analyte prediction is:
- the calibrations are developed from a set of exemplar absorbance spectra with reference blood analyte values and pre-assigned classification definitions. This set, denoted the "calibration set,” must have sufficient samples to completely represent the subject population and the range of physiological states in the subject population.
- the p different calibration models are developed individually from the measurements assigned to each of the p classes. The models are realized using known methods including principal component regression (see, for example, H. Martens, T. Naes, Multivariate Calibration. New York, John Wiley and Sons (1989)), partial least squares regression (see, for example, P. Geladi, B. Kowalski, Partial least-squares regression: a tutorial, Analytica Chimica Acta, 185, pp. 1-17 (1986)), and artificial neural networks (see, for example, S. Haykin, Neural Networks: A Comprehensive Foundation. Upper Saddle River, NJ, Prentice-Hall (1994)).
- the various models associated with each class are evaluated on the basis of an independent test set or cross validation and the best set of models are incorporated into the Intelligent Measurement System.
- Each class of subjects then has a calibration model specific to it.
- the calibration is passed a vector of memberships rather than a single estimated class.
- the vector, c is used to determine an adaptation of the calibration model suitable for blood analyte prediction or an optimal combination of several blood analyte predictions.
- the membership vector and the preprocessed absorbance spectrum are both used by a single calibration 70 for blood analyte prediction. The calculation is given by:
- y g(c, ⁇ ) ( 7 )
- g(») is a nonlinear mapping determined through nonlinear regression, nonlinear partial least squares or artificial neural networks. The mapping is developed from the calibration set described previously and is generally complex.
- the preferred realization, shown in Fig. 8, has separate calibrations 80 for each class similar to that shown in Fig. 6.
- each calibration is generated using all measurements in the calibration set by exploiting the membership vector assigned to each measurement.
- the membership vector is used to determine an optimal combination of the p blood analyte predictions from all classes through defuzzification 81. Therefore, during calibration development a given measurement of the calibration set has the opportunity to impact more than one calibration model. Similarly, during prediction more than one calibration model is used to generate the blood analyte estimate.
- Each of the p calibration models of Fig. 8 is developed using the entire calibration. However, when the kth calibration model is calculated, the calibration measurements are weighted by their respective membership in the kth class. As a result, the influence of a sample on the calibration model of a particular class is a function of its membership in the class.
- weighted least squares is applied to calculate regression coefficients and, in the case of factor based methods, the covariance matrix (see, for example, N. Draper, H. Smith. Applied Regression Analysis. 2 nd Ed., John Wiley and Sons, New York (1981)).
- M is the matrix of the first n eigen vectors of P.
- the weighted covariance matrix P is determined through:
- the regression matrix, B is determined through:
- defuzzification is a mapping from the vector of blood analyte predictions and the vector of class memberships to a single analyte prediction.
- the defuzzifier can be denoted as transformation such that:
- d(») is the defuzzification function
- c is the class membership vector
- y k is the blood analyte prediction of the kth calibration model.
- Existing methods of defuzzification such as the centroid or weighted average, are applied for small calibration sets. However, if the number of samples is sufficient, d(») is generated through a constrained nonlinear model.
- the algorithm manager 10 (see Fig. 1 ) is responsible for reporting results to the operator, coordinating all algorithmic events, monitoring the performance based on the class, and adapting the rules as necessary. Both class estimates and blood analyte predictions are reported to the algorithm manager.
- the classifier also generates a measure of the certainty of class membership. If the measurement does not fit into one of the existing classes the supervisor notifies the operator that the prediction is invalid. Further spectral measurements are taken to determine if the error is due to the instrument, measurement technique or sample. This error detection and correction algorithm is used to determine if more classes are necessary or if the instrument requires maintenance.
- IMS Intelligent Measurement System for Blood Analyte Prediction
- a Crisp Classification System is used to determine one of four suitable prediction models.
- the second realization denoted the Fuzzy Classification System, employs fuzzy membership rules to determine the class membership in each of six classes.
- the outputs of the corresponding six prediction models are combined using a defuzzification procedure to produce a single blood glucose prediction.
- the two implementations are specific to the prediction of blood glucose concentration.
- the invention is appropriate for the prediction of all blood analytes and other biological and other compounds that absorb in the NIR.
- the Intelligent Measurement System is implemented in a scanning spectrometer which determines the NIR absorbance spectrum of the subject forearm through a diffuse reflectance measurement.
- a block diagram of the integrated instrumentation and the IMS is shown in Figure 9 and includes the general instrument components, the IMS 90 and a display system (output device) 91.
- the instrument employs a quartz halogen lamp 92, a monochromater 93, a subject interface module 97, detector optics 98, and InGAs detectors 94.
- the detected intensity from the subject 95 is converted to a voltage through analog electronics 94 and digitized through a 16-bit A/D converter 96.
- the spectrum is passed to the IMS for processing and results in either a glucose prediction or a message indicating an invalid scan.
- the IMS can be employed with existing NIR spectrometers that are commercially available, including a Perstorp Analytical NIRS 5000 spectrometer or a Nicolet Magna-IR 760 spectrometer.
- existing NIR spectrometers including a Perstorp Analytical NIRS 5000 spectrometer or a Nicolet Magna-IR 760 spectrometer.
- Figure 10 depicts an implementation of the IMS that involves subject classification through crisp or classical decision rules denoted IMS-CC.
- the objective of the classification is to determine which of four calibration models are applied for analyte prediction. This decision is accomplished through feature extraction 102, 103, classification 100, and application of a set of decision rules 104.
- PCA principal components analysis
- Spectra with significant deviations from the system's PCA model are designated as unsatisfactory and rejected.
- Features related to the subjects sex and age are extracted through factor based techniques (PCA and PLS) after preprocessing 105, 106.
- the features are supplied to a set of decision rules 104 that determine which one of four classes 107, 108, 109, 110 best represents the absorbance spectrum of the subject, given the current state and structure of the tissue volume sampled during the measurement. While this implementation depicts four classes, the invention extends to the number of classes and features that are necessary for glucose prediction accuracy. Additional classes, for example, may be determined based on features related to hydration, skin thickness, thickness of adipose tissue, volume fraction of blood in tissue, blood pressure, hematocrit levels and others.
- the absorbance spectrum is also preprocessed (Preprocessing 1) 105 in a manner suitable for calibration.
- Preprocessing 1 The absorbance spectrum is also preprocessed (Preprocessing 1) 105 in a manner suitable for calibration.
- the present implementation contains one method of preprocessing for all calibration models, the preferred realization supplies separate preprocessing methods for each calibration model.
- the calibration model that is applied to the spectrum is determined based on the classification described above and the model output is the glucose prediction.
- the implementation shown in Figure 10 contains four calibration models associated with the four classes. However, in the general case an arbitrary number of calibrations are used equal to the number of classes needed to represent the spectral variation of individuals using the instrument.
- the measured NIR spectrum m is a vector containing absorbance values evenly distributed in the wavelength range 1100-2500 nm.
- the detection of spectral outliers is performed through a principal components analysis and an analysis of the residuals.
- the spectrum m is projected onto seven eigenvectors, contained in the matrix o, that were previously developed through a principal components analysis (on a calibration set of exemplary absorbance spectra) and are stored in the IMS-CC. The calculation is given by:
- the sample is reported by the algorithm manager to be an outlier.
- the first feature is the result of a classification of the subject into male and female categories and involves spectral preprocessing, decomposition through principal components analysis, and classification through linear discriminant analysis.
- the feature is not a determination of the subject's sex but rather provides a measure of the tissue volume sampled as compared to that of other subjects.
- the process receives the absorbance spectrum m from the outlier detection system 111.
- Wavelength selection 112 is applied to truncate the spectral range to regions with significant absorption due to fat in adipose tissue (1100 to 1400 nm).
- the spectrum is next processed through multivariate scatter correction 113 (see P. Geladi, D. McDougall, H. Martens, Linearization and Scatter- Correction for Near-Infrared Reflectance Spectra of Meat, Applied Spectroscopy, vol. 39, pp. 491-500, 1985) through a rotation that fits it to the expected or reference spectrum m contained in the Intelligent System and determined from a prior set of examplary samples.
- the spectrum is then corrected through:
- x is the processed absorbance spectrum.
- the processed spectrum is projected onto the eigenvectors, p k , that were previously developed through a principal components analysis 114 (on a calibration set of exemplary absorbance spectra) and are stored in the IMS-CC.
- the calculation shown in Figure 11 , produces the 1 by N vector of scores, xpc.
- the scores are rotated through a cross product with the discriminant , w, as depicted in Figure 11 to produce the scalar, L (115).
- the second feature extraction process 103 (see Fig. 10) is represented in Figure 12 and involves the prediction of the subject's age using a linear model developed through partial least squares regression (PLS).
- PLS partial least squares regression
- the wavelength range is truncated120 to the 1100 to 1800 nm region.
- the subject's age is predicted through a calibration model that is part of the IMS-CC.
- the model developed through PLS on a calibration set of exemplary samples, consists of a set of coefficients contained in the vector w and is applied as shown in Figure 12 to produce the age prediction a 121.
- the result of the classification is the calculated feature, z 2 , which assumes vales of zero or one corresponding to a classification of "old” 123 or "young” 124 respectively.
- the membership rules 104 determine the appropriate calibration model to predict the blood glucose concentration from the measured absorbance spectrum. Based on the two features, z, and z 2 , four classes are possible. The consequence of the decision it the selection of one of four calibration models to use to predict the blood glucose concentration denoted PLS 1-4.
- the absorbance spectrum is processed specifically for calibration through MSC as described above and a 31 -point Savisky-Golay first derivative in the form of a finite impulse response filter 125 (see A. Savitzky, M. Golay, Smoothing and Differentiation of Data by Simplified Least Squares Procedures, Anal. Chem., vol. 36, no. 8, pp. 1627-1639, 1964).
- the result is mean-centered by subtracting, x, the mean processed absorbance spectrum from a calibration set of exemplary samples that is stored in the IMS-CC.
- Wavelength selection is performed to include the following wavelengths: 1100-1350 nm, 1550-1750 nm and 2050-2375 nm.
- one of the four calibration models is selected for application as depicted in the two selectors 126, 127 of Figure 10.
- the four calibration models 107-110 each consist of a 1xN vector of coefficients that map x to a prediction of glucose. Each set of coefficients was developed using samples (from a calibration set) that were classified as belonging to its associated class. Therefore, the models are limited to predicting glucose concentration levels on subjects that are classified in their respective classes.
- the blood glucose prediction Given the processed spectrum, x, the classification, c, and the model coefficients w c associated with c, the blood glucose prediction is given by:
- the system shown in Figure 14 denoted the IMS-FC, employs fuzzy sets to define a continuum of grades in each of the classes. Rather than categorizing subjects into distinct and independent groups, this system determines the degree of membership of a particular subject in each of six classes (150-155). Therefore, each subject shares membership in every class and each of the parallel calibration models has the opportunity to contribute to the prediction of the blood analyte based.
- the weighted combination (based on class membership) of the prediction of all calibration models in the system produces an apparent continuum of calibration models. Subjects falling mid-point between two classes, for example, are predicted using both rather than one of the two (calibration models) and produce a prediction with a greater level of confidence. Similarly, the calibrations are created through a weighted principal components regression (WPCR) and are not exclusive to a distinct population.
- WPCR weighted principal components regression
- the fuzzy system classifies exclusively on the basis of spectral information.
- the measured absorbance spectrum is preprocessed for feature extraction.
- the features in this implementation are continuous (calculated) variables related to the absorption of body fat that is manifested spectrally and the apparent age of the sampled tissue volume. Fuzzification occurs through a set of membership functions that produce five membership values associated with the subsets male, female, young, middle aged and old. These membership values are transformed through decision rules 146 to produce the degree of class membership in each of six classes.
- the spectrum is also preprocessed in a manner suitable for calibration and applied to each of the six calibration models.
- the results are combined through the process of defuzzification 149 in which the degree of class membership is used to weight the influence of each prediction.
- the invention may use an arbitrary number of each in the configuration shown to produce a blood analyte predictions. Further, the invention covers the use of fuzzy classification for the purpose of blood analyte prediction or other analytes determinations.
- the measured NIR spectrum, m, 111 is a vector containing absorbance values evenly distributed in the wavelength range 1100-2500 nm.
- the detection 99 of spectral outliers is performed through a principal components analysis and an analysis of the residuals.
- the spectrum m is projected onto seven eigenvectors, contained in the matrix o that were previously developed through a principal components analysis on a calibration set and stored in the IMS- FC. The calculation is given by:
- the sample is reported by the algorithm manager to be an outlier.
- the first feature for the IMS-FC is related to the fat stored in adipose tissue as manifested through absorption bands in the 1100-1380 nm range. This feature is extracted, as shown in Figure 15A, by performing multiplicative scatter correction 160 (described previously) on the 1100-1380 nm range.
- the absorbance value corresponding to the wavelength 1208 nm 161 is the value of the feature, z 3 , associated with the measured absorbance spectrum.
- the second feature extraction shown in Figure 15B, produces a prediction of the subject's age based on the measured absorbance spectrum.
- the wavelength range is truncated to the 1 100 to 1800 nm region 162.
- the subject's age is predicted through a calibration model 163 that is part of the IMS-FC.
- the model developed through PLS on a calibration set of representative samples, consists of a set of coefficients contained in the vector w and is applied as shown in Figure 12 to produce the age prediction z 4 . Fuzzy Membership Functions
- the fuzzy membership functions 142, 145 are used to determine the degree of membership of the subject in specific sub-sets that are later combined through the decision rules.
- Each membership function maps the feature input to a value between 0 and 1 through a gaussian function.
- the general equation employed to represent the membership functions is:
- y is the degree of membership in a sub-set
- z is the feature used to determine membership
- ⁇ is the mean or center of the fuzzy sub-set
- ⁇ is the standard deviation
- Membership Functions 1 represent the subject's sex 170 using two sub-sets (male 173 and female 174).
- Membership Functions 2 uses three subsets, described below, to represent the age 171 of the subject. The degree of membership in each sub-set is calculated through Equation (15) and used through fuzzy operators and decision rules to assign class membership.
- the first set of membership functions 170 are gaussian functions that determine the degree of membership in the male and female sub-sets based on the feature related to the absorption of fat (Feature 3).
- the mean and standard deviation associated with each sub-set were determined from a large population of subjects and are listed in Table 1. As shown in the figure, the greater z the more likely the subject falls into the category of females. Conversely, lower values of z give lower membership in the category of females and higher in the category of males.
- the second set of membership functions 171 are gaussian functions that determine the degree of membership in the categories young, middle aged and old based on the feature representing the prediction of age (Feature 4).
- the mean and standard deviation associated with each of the three categories were determined qualitatively based on inspection of a target population of subjects and are listed in Table 2.
- This information is provided to the algorithm manager and indicates that the subject belongs to a class for which a calibration model has not been constructed. For the current implementation when y ⁇ 0.1 for all sub-sets the prediction is assigned a low confidence level.
- the membership functions described have been designed for a specific population of subjects and cannot be generalized to all potential individuals.
- the invention covers the arbitrary use of membership functions to assign a degree of membership in a given class to a subject for blood analyte prediction.
- Other subsets include the level of hydration, skin thickness, thickness of adipose tissue, volume fraction of blood in tissue, blood pressure, and hematocrit levels.
- the number of sub-sets per general set can also be increased arbitrarily depending on the necessarily level of discrimination for the accurate prediction of blood analytes.
- the output of Membership Functions 1 and Membership Functions 2 are two and five membership values, respectively, that are associated with the sex and age related sub-sets.
- the decision rules 146 are a set of operators and inferences that combine the membership values of the sub-sets into the class membership used for blood glucose prediction.
- the specific rules, given in Error! Reference source not found., are all possible combinations of the sub-sets described previously.
- the rules employ the fuzzy "and" operator which is implemented by determining the minimum of the two sub-set membership values comprising its antecedent.
- class membership assignment process assume that a subject was determined to have values for features 3 and 4 of 0.55 AU and 60 years respectively. From Figure 16, the membership values in the male and female sub- sets are approximately 0.82 and 0.3 respectively. Similarly, the membership values for the young, middle aged and old sub-sets are 0, 0.6 and 0.35. From the rules in Figure 17 the following class membership values are calculated:
- the second calibration model (WPCR2) 151 was created using spectra most similar to the measured spectrum.
- the measured spectrum also has membership in the third, fifth, and sixth classes. The degree of membership in the classes is used subsequently to determine the combination of calibration models for blood analyte prediction.
- the absorbance spectrum is processed specifically for calibration through MSC as described above and a 31 -point Savisky-Golay first derivative in the form of a finite impulse response filter (see A. Savitzky, M. Golay, Smoothing and Differentiation of Data by Simplified Least Squares Procedures, Anal. Chem., vol. 36, no. 8, pp.
- the result is mean-centered by subtracting, x, the mean processed absorbance spectrum that is stored in the IMS-FC and was determined from a calibration set. Wavelength selection is performed to include the following wavelengths: 1100-1350 nm, 1550-1750 nm and 2050-2375 nm.
- the calibration process in Figure 14 involves the prediction of the blood analyte using all of the calibration models. Therefore, the calibration block represents a single input-multiple-output operation that produces six blood analyte predictions.
- the six calibration models each consist of a 1xN vector of coefficients that map x to a prediction of the blood glucose concentration.
- Each set of coefficients was developed using all samples in a population (the calibration set of exemplary samples). However, each calibration sample was weighted using weighted principal components regression as described in Equations 8-10. Therefore, the models are associated with the six classes.
- the blood glucose prediction for the cth model is given by:
- Defuzzification 149 is used to aggregate the multiple predictions into one through the degree of class membership. Prior to defuzzifying, the vector of class membership values d is normalized to unit length. The defuzzification process is shown in Figure 18 and results in a prediction that is influenced the most by the calibration prediction associated with the class with the high degree of class membership. The present implementation heavily biases the prediction in favor of the calibration model output with the highest degree of class membership. However, other implementations are also suggested by the invention (i.e. a simple average of all predictions or the average of all predictions corresponding to a membership value greater than a specified value).
- Diabetic subjects (266) of diverse age, sex, and ethnicity were recruited at a local diabetic care facility and detailed demographic information about each participant was recorded.
- Four replicate absorbance spectra were measured on each subject's forearm and the number of samples per participant was limited to one.
- Venous blood draws, taken concurrently, were analyzed chemically via a hexakinase enzymatic method by an independent blood laboratory to determine reference glucose concentrations. The mean glucose concentration of the population was 120 mg/dL and the standard deviation 50 mg/dL.
- the data was divided into calibration and test sets using random selection.
- the calibration set was used to construct the models necessary for classification and calibration in Figure 10 and Figure 14.
- the test set was applied to the constructed systems and used to evaluate for evaluation.
- PLS was applied to the calibration set and the number of factors (20) was selected by optimizing the prediction error through crossvalidation (leave-one-out).
- the final PLS calibration model was constructed using all calibration samples and 20 factors. The calibration model was applied to both the calibration and test sets and the results listed in Table 3.
- IMS-CC corresponds to the system with crisp classification (Fig. 10).
- IMS-FC includes fuzzy classification (Fig. 14).
- the outliers described in the prior section were removed and the calibration set was used to determine the parameters, eigenvectors and calibration models of the structure in shown in Figure 10.
- the calibration set was then classified using the membership rules of Figure 13 and separated into four individual subsets.
- a calibration model was developed for each subset or class corresponding to calibration models PLS1-4 in Figure 10. Each calibration model was developed through PLS and factor selection was performed through cross validation on the calibration set.
- the constructed IMS-CC was applied to the calibration and test sets and the results are listed in Table 3.
- the test set performance is seen to improve markedly over the base calibration indicating a performance improvement due to the system of prediction.
- the calibration set was then classified using the membership functions and rules of Figure 16 and Figure 17 to produce a vector of class membership values for each sample in the calibration set.
- the six calibration models shown in Figure 14 were developed using Equations 8-10 (weighted principal component regression). Each of the six calibration models was optimized through cross validation on the calibration set and the final model was produced using all calibration set samples and the optimal number of factors.
- the constructed IMS-FC was applied to the calibration and test sets and the results are listed in Table 3.
- the test set performance is seen to improve markedly over both the base calibration and the IMS-CC system indicating a performance improvement due to the use of a fuzzy classification system. Discussion
- the results in Table 3 demonstrate an improvement over the standard PLS model in accuracy, precision and significance.
- the IMS employing a fuzzy classification system (IMS-FC) was shown to outperform the IMS that used a crisp system. Since the IMS-FC used six classes as opposed to the four used by IMS-CC the results do not provide a final judgement regarding the performance of crisp versus fuzzy systems.
- the number of data points is limited and the dimensionality of the problem great, the number of models that can be generated by IMS-CC is limited since an increase in classes causes a decrease in the data used to perform the calibrations associated with the classes.
- the IMS-FC does not share this limitation to the same extent since all samples are used to create the calibration models.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Analytical Chemistry (AREA)
- Mathematical Physics (AREA)
- Evolutionary Computation (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Fuzzy Systems (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0008186-8A BR0008186A (pt) | 1999-01-22 | 2000-01-19 | Sistema e processo para medições não-invasivas dos elementos integrantes do sangue |
NZ513092A NZ513092A (en) | 1999-01-22 | 2000-01-19 | System and method for noninvasive blood analyte measurements |
EP00904453A EP1143850A1 (de) | 1999-01-22 | 2000-01-19 | Gerät und verfahren zur nichtinvasiven messung von blutbestandteilen |
IL14440100A IL144401A0 (en) | 1999-01-22 | 2000-01-19 | System and method for noninvasive blood analyte measurements |
AU26209/00A AU754677B2 (en) | 1999-01-22 | 2000-01-19 | System and method for noninvasive blood analyte measurements |
JP2000594375A JP2002535023A (ja) | 1999-01-22 | 2000-01-19 | 非侵襲的血液分析測定のためのシステムおよび方法 |
CA002358473A CA2358473A1 (en) | 1999-01-22 | 2000-01-19 | System and method for noninvasive blood analyte measurements |
IL144401A IL144401A (en) | 1999-01-22 | 2001-07-18 | System and method for noninvasive blood analyte measurements |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11688399P | 1999-01-22 | 1999-01-22 | |
US60/116,883 | 1999-01-22 | ||
US09/359,191 | 1999-07-22 | ||
US09/359,191 US6280381B1 (en) | 1999-07-22 | 1999-07-22 | Intelligent system for noninvasive blood analyte prediction |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000042907A1 true WO2000042907A1 (en) | 2000-07-27 |
WO2000042907A9 WO2000042907A9 (en) | 2001-10-25 |
Family
ID=26814720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001378 WO2000042907A1 (en) | 1999-01-22 | 2000-01-19 | System and method for noninvasive blood analyte measurements |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1143850A1 (de) |
JP (1) | JP2002535023A (de) |
AU (1) | AU754677B2 (de) |
BR (1) | BR0008186A (de) |
CA (1) | CA2358473A1 (de) |
IL (2) | IL144401A0 (de) |
NZ (1) | NZ513092A (de) |
TW (1) | TW498156B (de) |
WO (1) | WO2000042907A1 (de) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001063251A1 (en) * | 2000-02-25 | 2001-08-30 | Instrumentation Metrics, Inc. | A non-invasive method of determining skin thickness and characterizing layers of skin tissue in vivo |
WO2001092859A1 (en) * | 2000-06-02 | 2001-12-06 | Medicometrics Aps | Method and system for classifying a biological sample |
WO2001050948A3 (en) * | 2000-01-12 | 2002-01-17 | Instrumentation Metrics Inc | Non-invasive method of determining skin thickness and characterizing skin tissue layers |
WO2002023971A2 (en) * | 2000-09-18 | 2002-03-28 | Instrumentation Metrics, Inc. | A multi-tier method of classifying sample spectra for non-invasive blood analyte prediction |
WO2002025233A2 (en) * | 2000-09-18 | 2002-03-28 | Sensys Medical, Inc. | Method of characterizing spectrometers and providing calibration models |
WO2002065090A2 (en) | 2001-01-26 | 2002-08-22 | Sensys Medical | Noninvasive measurement of glucose through the optical properties of tissue |
WO2002069796A2 (en) * | 2001-03-01 | 2002-09-12 | University Of Massachusetts | Correction of spectra for subject diversity |
WO2003041582A1 (fr) * | 2001-11-15 | 2003-05-22 | Matsushita Electric Works, Ltd. | Technique et appareil de mesure de la concentration d'un composant biologique |
EP1372471A1 (de) * | 2001-04-03 | 2004-01-02 | Sensys Medical, Inc. | Mehrstufige methode zur entwicklung lokalisierter kalibrationsmodelle für die nicht-invasive blutanalyten-prädiktion |
US7206623B2 (en) | 2000-05-02 | 2007-04-17 | Sensys Medical, Inc. | Optical sampling interface system for in vivo measurement of tissue |
EP1805499A2 (de) * | 2004-10-21 | 2007-07-11 | Optiscan Biomedical Corporation | Verfahren und vorrichtung zur bestimmung einer analytkonzentration in einer probe mit interferierender substanz |
US7383069B2 (en) | 1997-08-14 | 2008-06-03 | Sensys Medical, Inc. | Method of sample control and calibration adjustment for use with a noninvasive analyzer |
EP2177895A3 (de) * | 2005-02-14 | 2010-12-15 | Optiscan Biomedical Corporation | Verfahren und Vorrichtung zum Nachweis von mehreren Analyten |
CN102713915A (zh) * | 2009-12-21 | 2012-10-03 | 霍夫曼-拉罗奇有限公司 | 用于运行在收集设备上的结构化收集规程的实施、执行、数据收集以及数据分析的管理方法和系统 |
US8775096B2 (en) | 2009-10-29 | 2014-07-08 | Hoya Corporation | Auxiliary diagnostic apparatus and auxiliary diagnostic method |
US9091676B2 (en) | 2010-06-09 | 2015-07-28 | Optiscan Biomedical Corp. | Systems and methods for measuring multiple analytes in a sample |
US9117015B2 (en) | 2008-12-23 | 2015-08-25 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US9659037B2 (en) | 2008-12-23 | 2017-05-23 | Roche Diabetes Care, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US9913604B2 (en) | 2005-02-14 | 2018-03-13 | Optiscan Biomedical Corporation | Analyte detection systems and methods using multiple measurements |
CN109211830A (zh) * | 2018-08-01 | 2019-01-15 | 嘉兴市皮毛和制鞋工业研究所 | 一种主成分分析和多类判别联用鉴别易混毛皮的方法 |
US10475529B2 (en) | 2011-07-19 | 2019-11-12 | Optiscan Biomedical Corporation | Method and apparatus for analyte measurements using calibration sets |
CN113347919A (zh) * | 2018-08-07 | 2021-09-03 | 金达中华有限公司 | 血液动力持续监测非侵略性系统和方法 |
US11350822B2 (en) | 2008-12-23 | 2022-06-07 | Roche Diabetes Care, Inc. | Status reporting of a structured collection procedure |
US11559186B2 (en) | 2015-08-13 | 2023-01-24 | Hoya Corporation | Evaluation value calculation device and electronic endoscope system |
US11571108B2 (en) | 2015-08-13 | 2023-02-07 | Hoya Corporation | Evaluation value calculation device and electronic endoscope system |
WO2023237980A1 (fr) * | 2022-06-10 | 2023-12-14 | Aryballe | Procédé et programme d'ordinateur pour l'étalonnage d'un dispositif électronique de caractérisation d'un fluide, dispositif électronique correspondant |
WO2024052898A1 (en) * | 2022-09-06 | 2024-03-14 | Refana Inc. | System and method for non-invasive quantification of blood biomarkers |
WO2024127396A1 (en) * | 2022-12-12 | 2024-06-20 | Refana, Inc. | System and method for generating a prediction model based on an input dataset |
US12112834B2 (en) | 2022-09-06 | 2024-10-08 | Refana, Inc. | System and method for non-invasive quantification of blood biomarkers |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8718738B2 (en) | 2002-03-08 | 2014-05-06 | Glt Acquisition Corp. | Method and apparatus for coupling a sample probe with a sample site |
US7697966B2 (en) | 2002-03-08 | 2010-04-13 | Sensys Medical, Inc. | Noninvasive targeting system method and apparatus |
US8504128B2 (en) | 2002-03-08 | 2013-08-06 | Glt Acquisition Corp. | Method and apparatus for coupling a channeled sample probe to tissue |
EP1499231A4 (de) | 2002-03-08 | 2007-09-26 | Sensys Medical Inc | Kompaktes gerät für die nichtinvasive messung von glukose durch nahinfrarot-spektroskopie |
JP3566276B1 (ja) | 2003-05-07 | 2004-09-15 | 株式会社日立製作所 | 血糖値測定装置 |
JP3566277B1 (ja) | 2003-06-23 | 2004-09-15 | 株式会社日立製作所 | 血糖値測定装置 |
JP3566278B1 (ja) | 2003-07-11 | 2004-09-15 | 株式会社日立製作所 | 血糖値測定装置 |
JP3590047B1 (ja) | 2003-09-24 | 2004-11-17 | 株式会社日立製作所 | 光学測定装置及びそれを用いた血糖値測定装置 |
EP1522254A1 (de) | 2003-10-08 | 2005-04-13 | Hitachi, Ltd. | Vorrichtung zur Messung des Blutzuckerspiegels |
JP3557424B1 (ja) | 2004-02-17 | 2004-08-25 | 株式会社日立製作所 | 血糖値測定装置 |
JP3557425B1 (ja) | 2004-02-17 | 2004-08-25 | 株式会社日立製作所 | 血糖値測定装置 |
JP3590054B1 (ja) | 2004-02-26 | 2004-11-17 | 株式会社日立製作所 | 血糖値測定装置 |
US8868147B2 (en) | 2004-04-28 | 2014-10-21 | Glt Acquisition Corp. | Method and apparatus for controlling positioning of a noninvasive analyzer sample probe |
US7215983B2 (en) | 2004-06-30 | 2007-05-08 | Hitachi, Ltd. | Blood sugar level measuring apparatus |
US7251517B2 (en) | 2004-06-30 | 2007-07-31 | Hitachi, Ltd. | Blood sugar level measuring apparatus |
US8597190B2 (en) | 2007-05-18 | 2013-12-03 | Optiscan Biomedical Corporation | Monitoring systems and methods with fast initialization |
TWI689439B (zh) * | 2018-07-16 | 2020-04-01 | 巨大機械工業股份有限公司 | 避震裝置 |
CN113702317B (zh) * | 2021-08-30 | 2023-10-27 | 中国农业科学院农业信息研究所 | 一种流域面源污染组分传感器、监测系统及方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013739A1 (de) * | 1993-11-16 | 1995-05-26 | Jenoptik Gmbh | Verfahren und anordnung zur nichtinvasiven, transkutanen bestimmung von stoffkonzentrationen in körperflüssigkeit oder gewebe des menschen |
US5435309A (en) * | 1993-08-10 | 1995-07-25 | Thomas; Edward V. | Systematic wavelength selection for improved multivariate spectral analysis |
US5576544A (en) * | 1989-01-19 | 1996-11-19 | Futrex, Inc. | Method for providing general calibration for near infrared instruments for measurement of blood glucose |
US5606164A (en) * | 1996-01-16 | 1997-02-25 | Boehringer Mannheim Corporation | Method and apparatus for biological fluid analyte concentration measurement using generalized distance outlier detection |
WO1997028437A1 (en) * | 1996-02-02 | 1997-08-07 | Instrumentation Metrics, Inc. | Method and apparatus for multi-spectral analysis in noninvasive infrared spectroscopy |
-
2000
- 2000-01-19 JP JP2000594375A patent/JP2002535023A/ja active Pending
- 2000-01-19 CA CA002358473A patent/CA2358473A1/en not_active Abandoned
- 2000-01-19 AU AU26209/00A patent/AU754677B2/en not_active Ceased
- 2000-01-19 EP EP00904453A patent/EP1143850A1/de not_active Ceased
- 2000-01-19 IL IL14440100A patent/IL144401A0/xx active IP Right Grant
- 2000-01-19 NZ NZ513092A patent/NZ513092A/xx unknown
- 2000-01-19 BR BR0008186-8A patent/BR0008186A/pt not_active IP Right Cessation
- 2000-01-19 WO PCT/US2000/001378 patent/WO2000042907A1/en active IP Right Grant
- 2000-02-01 TW TW089101109A patent/TW498156B/zh not_active IP Right Cessation
-
2001
- 2001-07-18 IL IL144401A patent/IL144401A/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576544A (en) * | 1989-01-19 | 1996-11-19 | Futrex, Inc. | Method for providing general calibration for near infrared instruments for measurement of blood glucose |
US5435309A (en) * | 1993-08-10 | 1995-07-25 | Thomas; Edward V. | Systematic wavelength selection for improved multivariate spectral analysis |
WO1995013739A1 (de) * | 1993-11-16 | 1995-05-26 | Jenoptik Gmbh | Verfahren und anordnung zur nichtinvasiven, transkutanen bestimmung von stoffkonzentrationen in körperflüssigkeit oder gewebe des menschen |
US5606164A (en) * | 1996-01-16 | 1997-02-25 | Boehringer Mannheim Corporation | Method and apparatus for biological fluid analyte concentration measurement using generalized distance outlier detection |
WO1997028437A1 (en) * | 1996-02-02 | 1997-08-07 | Instrumentation Metrics, Inc. | Method and apparatus for multi-spectral analysis in noninvasive infrared spectroscopy |
Non-Patent Citations (1)
Title |
---|
SCHLAGER KENNETH J ET AL: "Transcutaneous analyte measuring method (TAMM): a reflective, noninvasive, near-infrared blood chemistry analyzer", ULTRASENSITIVE INSTRUMENTATION FOR DNA SEQUENCING AND BIOCHEMICAL DIAGNOSTICS;SAN JOSE, CA, USA, vol. 2386, 1995, Proc SPIE Int Soc Opt Eng, pages 174 - 184, XP000911284 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7233816B2 (en) | 1997-08-14 | 2007-06-19 | Sensys Medical, Inc. | Optical sampling interface system for in vivo measurement of tissue |
US7383069B2 (en) | 1997-08-14 | 2008-06-03 | Sensys Medical, Inc. | Method of sample control and calibration adjustment for use with a noninvasive analyzer |
US6456870B1 (en) | 1999-07-22 | 2002-09-24 | Sensys Medical, Inc. | Non-invasive method of determining skin thickness and characterizing layers of skin tissue in vivo |
US6864978B1 (en) | 1999-07-22 | 2005-03-08 | Sensys Medical, Inc. | Method of characterizing spectrometer instruments and providing calibration models to compensate for instrument variation |
WO2001050948A3 (en) * | 2000-01-12 | 2002-01-17 | Instrumentation Metrics Inc | Non-invasive method of determining skin thickness and characterizing skin tissue layers |
WO2001063251A1 (en) * | 2000-02-25 | 2001-08-30 | Instrumentation Metrics, Inc. | A non-invasive method of determining skin thickness and characterizing layers of skin tissue in vivo |
US7206623B2 (en) | 2000-05-02 | 2007-04-17 | Sensys Medical, Inc. | Optical sampling interface system for in vivo measurement of tissue |
US6834237B2 (en) | 2000-06-02 | 2004-12-21 | Medicometrics Aps | Method and system for classifying a biological sample |
WO2001092859A1 (en) * | 2000-06-02 | 2001-12-06 | Medicometrics Aps | Method and system for classifying a biological sample |
CN100458409C (zh) * | 2000-09-18 | 2009-02-04 | 三西斯医学股份有限公司 | 表征频谱仪并提供定标模型的方法 |
WO2002025233A3 (en) * | 2000-09-18 | 2002-06-27 | Instrumentation Metrics Inc | Method of characterizing spectrometers and providing calibration models |
WO2002025233A2 (en) * | 2000-09-18 | 2002-03-28 | Sensys Medical, Inc. | Method of characterizing spectrometers and providing calibration models |
WO2002023971A2 (en) * | 2000-09-18 | 2002-03-28 | Instrumentation Metrics, Inc. | A multi-tier method of classifying sample spectra for non-invasive blood analyte prediction |
WO2002023971A3 (en) * | 2000-09-18 | 2003-10-23 | Instrumentation Metrics Inc | A multi-tier method of classifying sample spectra for non-invasive blood analyte prediction |
EP1442699A1 (de) * | 2000-09-18 | 2004-08-04 | Sensys Medical, Inc. | Verfahren zur Charakterisierung von Spektrometern und zur Bereitstellung von Kalibrierungsmodellen zur Kompensation der Variation von Instrumenten |
KR100893432B1 (ko) * | 2001-01-26 | 2009-04-17 | 센시스 메디칼 인코포레이티드 | 조직 샘플 중의 표적 분석 물질 특성의 비침습적 측정방법 및 이를 위한 장치 |
EP1364196A2 (de) * | 2001-01-26 | 2003-11-26 | Instrumentation Metrics, Inc. | Nichtinvasive messung von glucose durch die optischen eigenschaften von gewebe |
EP1364196A4 (de) * | 2001-01-26 | 2008-09-03 | Sensys Medical Inc | Nichtinvasive messung von glucose durch die optischen eigenschaften von gewebe |
WO2002065090A2 (en) | 2001-01-26 | 2002-08-22 | Sensys Medical | Noninvasive measurement of glucose through the optical properties of tissue |
WO2002069796A3 (en) * | 2001-03-01 | 2002-12-19 | Univ Massachusetts | Correction of spectra for subject diversity |
WO2002069796A2 (en) * | 2001-03-01 | 2002-09-12 | University Of Massachusetts | Correction of spectra for subject diversity |
EP1372471A4 (de) * | 2001-04-03 | 2009-11-04 | Sensys Medical Inc | Mehrstufige methode zur entwicklung lokalisierter kalibrationsmodelle für die nicht-invasive blutanalyten-prädiktion |
EP1372471A1 (de) * | 2001-04-03 | 2004-01-02 | Sensys Medical, Inc. | Mehrstufige methode zur entwicklung lokalisierter kalibrationsmodelle für die nicht-invasive blutanalyten-prädiktion |
WO2003041582A1 (fr) * | 2001-11-15 | 2003-05-22 | Matsushita Electric Works, Ltd. | Technique et appareil de mesure de la concentration d'un composant biologique |
EP1452135A1 (de) * | 2001-11-15 | 2004-09-01 | Matsushita Electric Works, Ltd. | Verfahren zur messung der konzentration eines biologischen bestandteils und gerät dafür |
US7333841B2 (en) | 2001-11-15 | 2008-02-19 | Matsushita Electric Works, Ltd. | Method and device for calculating a biological component density of a subject |
EP1452135A4 (de) * | 2001-11-15 | 2008-11-05 | Matsushita Electric Works Ltd | Verfahren zur messung der konzentration eines biologischen bestandteils und gerät dafür |
EP1805499A2 (de) * | 2004-10-21 | 2007-07-11 | Optiscan Biomedical Corporation | Verfahren und vorrichtung zur bestimmung einer analytkonzentration in einer probe mit interferierender substanz |
EP1805499A4 (de) * | 2004-10-21 | 2010-07-21 | Optiscan Biomedical Corp | Verfahren und vorrichtung zur bestimmung einer analytkonzentration in einer probe mit interferierender substanz |
EP2177895A3 (de) * | 2005-02-14 | 2010-12-15 | Optiscan Biomedical Corporation | Verfahren und Vorrichtung zum Nachweis von mehreren Analyten |
EP2302357A1 (de) * | 2005-02-14 | 2011-03-30 | Optiscan Biomedical Corporation | Verfahren und Vorrichtung zum Nachweis von mehreren Analyten |
US9913604B2 (en) | 2005-02-14 | 2018-03-13 | Optiscan Biomedical Corporation | Analyte detection systems and methods using multiple measurements |
US9117015B2 (en) | 2008-12-23 | 2015-08-25 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US11327931B2 (en) | 2008-12-23 | 2022-05-10 | Roche Diabetes Care, Inc. | Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof |
US11907180B2 (en) | 2008-12-23 | 2024-02-20 | Roche Diabetes Care, Inc. | Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof |
US9659037B2 (en) | 2008-12-23 | 2017-05-23 | Roche Diabetes Care, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US11350822B2 (en) | 2008-12-23 | 2022-06-07 | Roche Diabetes Care, Inc. | Status reporting of a structured collection procedure |
US10915505B2 (en) | 2008-12-23 | 2021-02-09 | Roche Diabetes Care, Inc. | Management method and system implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US10368745B2 (en) | 2008-12-23 | 2019-08-06 | Roche Diabetes Care Inc | Systems and methods for optimizing insulin dosage |
US10565170B2 (en) | 2008-12-23 | 2020-02-18 | Roche Diabetes Care, Inc. | Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof |
US8775096B2 (en) | 2009-10-29 | 2014-07-08 | Hoya Corporation | Auxiliary diagnostic apparatus and auxiliary diagnostic method |
CN102713915A (zh) * | 2009-12-21 | 2012-10-03 | 霍夫曼-拉罗奇有限公司 | 用于运行在收集设备上的结构化收集规程的实施、执行、数据收集以及数据分析的管理方法和系统 |
US9091676B2 (en) | 2010-06-09 | 2015-07-28 | Optiscan Biomedical Corp. | Systems and methods for measuring multiple analytes in a sample |
US10475529B2 (en) | 2011-07-19 | 2019-11-12 | Optiscan Biomedical Corporation | Method and apparatus for analyte measurements using calibration sets |
US11559186B2 (en) | 2015-08-13 | 2023-01-24 | Hoya Corporation | Evaluation value calculation device and electronic endoscope system |
US11571108B2 (en) | 2015-08-13 | 2023-02-07 | Hoya Corporation | Evaluation value calculation device and electronic endoscope system |
CN109211830A (zh) * | 2018-08-01 | 2019-01-15 | 嘉兴市皮毛和制鞋工业研究所 | 一种主成分分析和多类判别联用鉴别易混毛皮的方法 |
CN113347919A (zh) * | 2018-08-07 | 2021-09-03 | 金达中华有限公司 | 血液动力持续监测非侵略性系统和方法 |
WO2023237980A1 (fr) * | 2022-06-10 | 2023-12-14 | Aryballe | Procédé et programme d'ordinateur pour l'étalonnage d'un dispositif électronique de caractérisation d'un fluide, dispositif électronique correspondant |
FR3136555A1 (fr) * | 2022-06-10 | 2023-12-15 | Aryballe | Procédé et programme d’ordinateur pour l’étalonnage d’un dispositif électronique de caractérisation d’un fluide, dispositif électronique correspondant |
WO2024052898A1 (en) * | 2022-09-06 | 2024-03-14 | Refana Inc. | System and method for non-invasive quantification of blood biomarkers |
US12112834B2 (en) | 2022-09-06 | 2024-10-08 | Refana, Inc. | System and method for non-invasive quantification of blood biomarkers |
WO2024127396A1 (en) * | 2022-12-12 | 2024-06-20 | Refana, Inc. | System and method for generating a prediction model based on an input dataset |
Also Published As
Publication number | Publication date |
---|---|
WO2000042907A9 (en) | 2001-10-25 |
JP2002535023A (ja) | 2002-10-22 |
NZ513092A (en) | 2003-02-28 |
TW498156B (en) | 2002-08-11 |
AU2620900A (en) | 2000-08-07 |
CA2358473A1 (en) | 2000-07-27 |
AU754677B2 (en) | 2002-11-21 |
BR0008186A (pt) | 2001-11-06 |
IL144401A (en) | 2006-06-11 |
IL144401A0 (en) | 2002-05-23 |
EP1143850A1 (de) | 2001-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU754677B2 (en) | System and method for noninvasive blood analyte measurements | |
US6280381B1 (en) | Intelligent system for noninvasive blood analyte prediction | |
US6512936B1 (en) | Multi-tier method of classifying sample spectra for non-invasive blood analyte prediction | |
US6512937B2 (en) | Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction | |
USRE41333E1 (en) | Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction | |
EP1250082B1 (de) | Klassifizierung and charakterisierung von gewebe durch merkmale bezüglich adiposegewebe | |
US6501982B1 (en) | System for the noninvasive estimation of relative age | |
EP1250083B1 (de) | Geschlechtsbestimmung | |
US20060167350A1 (en) | Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction | |
US6697654B2 (en) | Targeted interference subtraction applied to near-infrared measurement of analytes | |
US6675029B2 (en) | Apparatus and method for quantification of tissue hydration using diffuse reflectance spectroscopy | |
EP1214579B1 (de) | Verfahren zum kalibrieren einer spektroskopievorrichtung | |
US6788965B2 (en) | Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes | |
US6442408B1 (en) | Method for quantification of stratum corneum hydration using diffuse reflectance spectroscopy | |
US20070179367A1 (en) | Method and Apparatus for Noninvasively Estimating a Property of an Animal Body Analyte from Spectral Data |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2358473 Country of ref document: CA Kind code of ref document: A Ref document number: 2358473 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 144401 Country of ref document: IL Ref document number: 26209/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 513092 Country of ref document: NZ Ref document number: 2000904453 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2000 594375 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2000904453 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/18-18/18, DRAWINGS, REPLACED BY NEW PAGES 1/17-17/17 |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 26209/00 Country of ref document: AU |